CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With Gene Mutations;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia Interventions:   Drug: Ivosidenib;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials